At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 78 enrolled
Drug / intervention
Acalabrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating Acalabrutinib and acalabrutinib and pembrolizumab combination for Ovarian Cancer. Completed, enrolled 78 participants across 2 sites.
Detailed Summary
To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartNov 2015
Primary CompletionJul 2018
Study CompletionOct 2018
TodayJul 2026
First PostedSep 1, 2015
Enrollment StartNov 1, 2015
Primary CompletionJul 1, 2018
Study CompletionOct 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 10.8 years ago
Interventions
Acalabrutinibdrug
acalabrutinib and pembrolizumab combinationdrug